S&P 500   3,274.77 (+0.87%)
DOW   26,977.39 (+0.60%)
QQQ   268.91 (+1.33%)
AAPL   110.60 (+2.20%)
MSFT   206.39 (+1.57%)
FB   251.05 (+0.61%)
GOOGL   1,428.10 (+0.37%)
AMZN   3,054.31 (+1.14%)
TSLA   399.95 (+3.14%)
NVDA   507.45 (+2.74%)
BABA   268.00 (-0.64%)
CGC   14.04 (-1.61%)
GE   6.09 (+0.50%)
MU   48.77 (-1.41%)
AMD   77.31 (+1.97%)
T   27.88 (-0.57%)
F   6.51 (-2.25%)
ACB   5.00 (-3.85%)
GILD   61.96 (-0.47%)
NFLX   477.41 (+0.92%)
DIS   122.93 (+0.36%)
BAC   23.37 (+0.13%)
BA   152.83 (+4.64%)
S&P 500   3,274.77 (+0.87%)
DOW   26,977.39 (+0.60%)
QQQ   268.91 (+1.33%)
AAPL   110.60 (+2.20%)
MSFT   206.39 (+1.57%)
FB   251.05 (+0.61%)
GOOGL   1,428.10 (+0.37%)
AMZN   3,054.31 (+1.14%)
TSLA   399.95 (+3.14%)
NVDA   507.45 (+2.74%)
BABA   268.00 (-0.64%)
CGC   14.04 (-1.61%)
GE   6.09 (+0.50%)
MU   48.77 (-1.41%)
AMD   77.31 (+1.97%)
T   27.88 (-0.57%)
F   6.51 (-2.25%)
ACB   5.00 (-3.85%)
GILD   61.96 (-0.47%)
NFLX   477.41 (+0.92%)
DIS   122.93 (+0.36%)
BAC   23.37 (+0.13%)
BA   152.83 (+4.64%)
S&P 500   3,274.77 (+0.87%)
DOW   26,977.39 (+0.60%)
QQQ   268.91 (+1.33%)
AAPL   110.60 (+2.20%)
MSFT   206.39 (+1.57%)
FB   251.05 (+0.61%)
GOOGL   1,428.10 (+0.37%)
AMZN   3,054.31 (+1.14%)
TSLA   399.95 (+3.14%)
NVDA   507.45 (+2.74%)
BABA   268.00 (-0.64%)
CGC   14.04 (-1.61%)
GE   6.09 (+0.50%)
MU   48.77 (-1.41%)
AMD   77.31 (+1.97%)
T   27.88 (-0.57%)
F   6.51 (-2.25%)
ACB   5.00 (-3.85%)
GILD   61.96 (-0.47%)
NFLX   477.41 (+0.92%)
DIS   122.93 (+0.36%)
BAC   23.37 (+0.13%)
BA   152.83 (+4.64%)
S&P 500   3,274.77 (+0.87%)
DOW   26,977.39 (+0.60%)
QQQ   268.91 (+1.33%)
AAPL   110.60 (+2.20%)
MSFT   206.39 (+1.57%)
FB   251.05 (+0.61%)
GOOGL   1,428.10 (+0.37%)
AMZN   3,054.31 (+1.14%)
TSLA   399.95 (+3.14%)
NVDA   507.45 (+2.74%)
BABA   268.00 (-0.64%)
CGC   14.04 (-1.61%)
GE   6.09 (+0.50%)
MU   48.77 (-1.41%)
AMD   77.31 (+1.97%)
T   27.88 (-0.57%)
F   6.51 (-2.25%)
ACB   5.00 (-3.85%)
GILD   61.96 (-0.47%)
NFLX   477.41 (+0.92%)
DIS   122.93 (+0.36%)
BAC   23.37 (+0.13%)
BA   152.83 (+4.64%)
Log in
NASDAQ:PRAH

PRA Health Sciences Stock Forecast, Price & News

$96.46
+0.40 (+0.42 %)
(As of 09/25/2020 01:26 PM ET)
Add
Compare
Today's Range
$94.99
Now: $96.46
$96.46
50-Day Range
$97.84
MA: $103.04
$108.65
52-Week Range
$58.67
Now: $96.46
$113.32
Volume3,166 shs
Average Volume422,631 shs
Market Capitalization$6.17 billion
P/E Ratio29.59
Dividend YieldN/A
Beta1.02
PRA Health Sciences, Inc., a contract research organization, provides outsourced clinical development and data solution services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services. It also provides strategic solutions, such as embedded, functional services provider, staff augmentation, and custom-built development solutions, as well as commercialization services; and early development services for Phase I and Phase IIa studies, and bioanalytical analysis. The Data Solutions segment offers data, analytics, technology, and consulting solutions to the life sciences market. Its services include market intelligence services, such as targeting and compensation, and pharmaceutical audit suite services; consulting and services comprising brand analytics, managed markets, commercial effectiveness, and scientific studies/clinical hubs; and technology-enabled products and services. PRA Health Sciences, Inc. conducts clinical trials in the areas of pharmaceutical development, including oncology, immunology, central nervous system, inflammation, respiratory, cardio metabolic, and infectious diseases. The company was formerly known as PRA Global Holdings, Inc. and changed its name to PRA Health Sciences, Inc. in July 2014. PRA Health Sciences, Inc. was founded in 1976 and is headquartered in Raleigh, North Carolina.
Read More
PRA Health Sciences logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.59 out of 5 stars


Industry, Sector and Symbol

Industry Commercial physical research
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PRAH
CUSIPN/A
Phone919-786-8200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$3.07 billion
Cash Flow$6.49 per share
Book Value$17.23 per share

Profitability

Net Income$243.02 million

Miscellaneous

Employees17,500
Market Cap$6.17 billion
Next Earnings Date11/4/2020 (Estimated)
OptionableOptionable
$96.46
+0.40 (+0.42 %)
(As of 09/25/2020 01:26 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PRAH News and Ratings via Email

Sign-up to receive the latest news and ratings for PRAH and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











PRA Health Sciences (NASDAQ:PRAH) Frequently Asked Questions

How has PRA Health Sciences' stock price been impacted by COVID-19 (Coronavirus)?

PRA Health Sciences' stock was trading at $88.68 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PRAH stock has increased by 8.7% and is now trading at $96.36.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of PRA Health Sciences?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PRA Health Sciences in the last year. There are currently 2 sell ratings, 6 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for PRA Health Sciences
.

When is PRA Health Sciences' next earnings date?

PRA Health Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020.
View our earnings forecast for PRA Health Sciences
.

How were PRA Health Sciences' earnings last quarter?

PRA Health Sciences Inc (NASDAQ:PRAH) announced its earnings results on Thursday, August, 6th. The medical research company reported $0.69 earnings per share for the quarter, beating analysts' consensus estimates of $0.64 by $0.05. The medical research company had revenue of $729.89 million for the quarter, compared to the consensus estimate of $716.12 million. PRA Health Sciences had a net margin of 6.86% and a return on equity of 25.01%. The company's quarterly revenue was down 4.4% on a year-over-year basis. During the same period in the prior year, the company earned $1.22 earnings per share.
View PRA Health Sciences' earnings history
.

What guidance has PRA Health Sciences issued on next quarter's earnings?

PRA Health Sciences issued an update on its FY20 earnings guidance on Thursday, August, 6th. The company provided EPS guidance of $4.35 to $4.55 for the period, compared to the Thomson Reuters consensus estimate of $4.37. The company issued revenue guidance of $3.07 billion to $3.13 billion, compared to the consensus revenue estimate of $3.07 billion.

What price target have analysts set for PRAH?

13 analysts have issued twelve-month price objectives for PRA Health Sciences' stock. Their forecasts range from $89.00 to $120.00. On average, they anticipate PRA Health Sciences' share price to reach $105.75 in the next year. This suggests a possible upside of 9.7% from the stock's current price.
View analysts' price targets for PRA Health Sciences
.

Are investors shorting PRA Health Sciences?

PRA Health Sciences saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 936,500 shares, an increase of 10.6% from the August 15th total of 846,400 shares. Based on an average trading volume of 311,500 shares, the short-interest ratio is currently 3.0 days. Approximately 1.5% of the company's shares are short sold.
View PRA Health Sciences' Short Interest
.

Who are some of PRA Health Sciences' key competitors?

What other stocks do shareholders of PRA Health Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PRA Health Sciences investors own include NVIDIA (NVDA), Alibaba Group (BABA), Adobe (ADBE), Applied Materials (AMAT), Abbott Laboratories (ABT), Walt Disney (DIS), Paypal (PYPL), Veeva Systems (VEEV), Pfizer (PFE) and AbbVie (ABBV).

Who are PRA Health Sciences' key executives?

PRA Health Sciences' management team includes the following people:
  • Mr. Colin Shannon, Chairman, CEO & Pres (Age 60)
  • Mr. Michael J. Bonello, Exec. VP, CFO & Corp. Sec. (Age 49)
  • Mr. Kent Thoelke, Exec. VP & Chief Scientific Officer
  • Mr. Thomas Byrne, VP of Legal Affairs
  • Christine Rogers, Director of PR & Corp. Communications

When did PRA Health Sciences IPO?

(PRAH) raised $306 million in an IPO on Thursday, November 13th 2014. The company issued 17,000,000 shares at $18.00 per share. Jefferies, Citigroup, KKR, UBS Investment Bank, Credit Suisse and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

What is PRA Health Sciences' stock symbol?

PRA Health Sciences trades on the NASDAQ under the ticker symbol "PRAH."

Who are PRA Health Sciences' major shareholders?

PRA Health Sciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (10.69%), NN Investment Partners Holdings N.V. (2.32%), NN Investment Partners Holdings N.V. (2.30%), Pendal Group Ltd (1.61%), Bank of New York Mellon Corp (1.18%) and Bamco Inc. NY (1.02%). Company insiders that own PRA Health Sciences stock include Christopher L Gaenzle, Colin Shannon, Fund Holdings LP Kkr and Michael J Bonello.
View institutional ownership trends for PRA Health Sciences
.

Which institutional investors are selling PRA Health Sciences stock?

PRAH stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Bank of America Corp DE, Bamco Inc. NY, First Trust Advisors LP, FMR LLC, Nuveen Asset Management LLC, Smith Asset Management Group LP, and UBS Group AG. Company insiders that have sold PRA Health Sciences company stock in the last year include Christopher L Gaenzle, Colin Shannon, and Michael J Bonello.
View insider buying and selling activity for PRA Health Sciences
.

Which institutional investors are buying PRA Health Sciences stock?

PRAH stock was acquired by a variety of institutional investors in the last quarter, including TimesSquare Capital Management LLC, Thrivent Financial for Lutherans, Bank of Nova Scotia, Bank of New York Mellon Corp, NN Investment Partners Holdings N.V., Canada Pension Plan Investment Board, NN Investment Partners Holdings N.V., and Man Group plc.
View insider buying and selling activity for PRA Health Sciences
.

How do I buy shares of PRA Health Sciences?

Shares of PRAH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is PRA Health Sciences' stock price today?

One share of PRAH stock can currently be purchased for approximately $96.36.

How big of a company is PRA Health Sciences?

PRA Health Sciences has a market capitalization of $6.16 billion and generates $3.07 billion in revenue each year. The medical research company earns $243.02 million in net income (profit) each year or $4.80 on an earnings per share basis. PRA Health Sciences employs 17,500 workers across the globe.

What is PRA Health Sciences' official website?

The official website for PRA Health Sciences is www.prahs.com.

How can I contact PRA Health Sciences?

PRA Health Sciences' mailing address is 4130 PARKLAKE AVENUE SUITE 400, RALEIGH NC, 27612. The medical research company can be reached via phone at 919-786-8200 or via email at [email protected]

This page was last updated on 9/25/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.